Olinvacimab, TTAC-0001


Indications: Solid tumors

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis.


Mechanism of action / Target

Olinvacimab is a direct VEGFR2 antagonist that block the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.


Development Status

PharmAbcine has multiple ongoing global clinical trials involving Olinvacimab. There are two Phase 1b studies taking place in combination with Pembrolizumab for the treatment of mTNBC (metastatic Triple Negative Breast Cancer) and rGBM (recurrent Glioblastoma) in Australia. Also, a Phase 2a mono study in Bevacizumab non-responding rGBM is currently ongoing in both Australia and the U.S. In September 2021, PharmAbcine received HREC clearance to initiate a Phase 2 Olinvacimab/Pembrolizumab combo trial for mTNBC patients in Australia. The company expects the first patient enrollment in 4Q21.


Publications

* The new interim data of Olinvacimab/Pembrolizumab Phase Ib combination trial at SABCS 2020

* The finalized data of Phase 2a Olinvacimab mono study in rGBM at SNO 2020

* The first interim data of Olinvacimab/Pembrolizumab Phase Ib combination trial at KSMO 2020




     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea


     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 


     COPYRIGHT BY PharmAbcine Inc.

     ALL RIGHTS RESERVE